Format

Send to

Choose Destination
Br J Haematol. 2014 May;165(3):358-63. doi: 10.1111/bjh.12753. Epub 2014 Jan 27.

A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.

Author information

1
Hematology/Oncology, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA.

Abstract

Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare subtype of non-Hodgkin lymphoma (NHL) with limited data on pathology and outcome. A multicentre retrospective study was undertaken to determine prognostic factors and the incidence of central nervous system (CNS) relapses. Data was retrospectively collected on patients from 8 US academic centres. Only patients with stage I/II disease (involvement of breast and localized lymph nodes) were included. Histologies apart from primary DLBCL were excluded. Between 1992 and 2012, 76 patients met the eligibility criteria. Most patients (86%) received chemotherapy, and 69% received immunochemotherapy with rituximab; 65% received radiation therapy and 9% received prophylactic CNS chemotherapy. After a median follow-up of 4·5 years (range 0·6-20·6 years), the Kaplan-Meier estimated median progression-free survival was 10·4 years (95% confidence interval [CI] 5·8-14·9 years), and the median overall survival was 14·6 years (95% CI 10·2-19 years). Twelve patients (16%) had CNS relapse. A low stage-modified International Prognostic Index (IPI) was associated with longer overall survival. Rituximab use was not associated with a survival advantage. Primary breast DLBCL has a high rate of CNS relapse. The stage-modified IPI score is associated with survival.

KEYWORDS:

breast; central nervous system; diffuse large B-cell lymphoma; lymphoma; rituximab

PMID:
24467658
PMCID:
PMC3990235
DOI:
10.1111/bjh.12753
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center